Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 15, 2026

Author Spotlight: An Economic and Efficient Method for Quantitative Evaluation of Bone Microarchitecture in a Murine Osteoporosis Model
06:59

Author Spotlight: An Economic and Efficient Method for Quantitative Evaluation of Bone Microarchitecture in a Murine Osteoporosis Model

Published on: September 8, 2023

3.6K

[Osteoporosis].

Brigitte Uebelhart1, Serge Ferrari1

  • 1Service des maladies osseuses, Département des spécialités de médecine, HUG, 1211 Genève 14.

Revue Medicale Suisse
|January 17, 2018
PubMed
Summary
This summary is machine-generated.

Osteoporosis treatment varies by drug and patient fracture risk. Stopping denosumab after ten years may increase early vertebral fracture risk, while teriparatide is more effective than risedronate for high-risk patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonates.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Insulin therapy improves bone microstructure and material properties without restoring whole-bone strength in male insulin-deficient Akita mice.

Bone·2026
Same author

The gut-bone axis: microbial metabolism and nutritional interventions for bone health.

Gut microbes·2026
Same author

Consensus statement on the application of artificial intelligence in osteoporosis screening and management: perspectives from the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Orthogeriatric Fracture Syndrome: A Large-Scale Bibliometric Analysis of a Proposed Concept for Cross-Disciplinary Awareness and Coordinated Care.

Journal of clinical medicine·2026
Same author

Precision and age-related changes of 3D-DXA reconstructions and FEA of the proximal femur in comparison to DXA.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Area of Science:

  • Endocrinology
  • Orthopedics
  • Pharmacology

Background:

  • The risk of a second fracture within two years of a first fracture is notably high.
  • Osteoporosis management requires careful consideration of individual patient fracture risk and therapeutic options.

Purpose of the Study:

  • To review the efficacy and risks associated with various osteoporosis treatments.
  • To compare the effectiveness of different pharmacological agents in preventing fractures.
  • To highlight specific fracture risks associated with certain osteoporosis medications.

Main Methods:

  • Literature review of clinical trials and observational studies on osteoporosis pharmacotherapy.
  • Analysis of treatment outcomes including fracture incidence, adverse events, and drug discontinuation effects.

More Related Videos

Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention
03:56

Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention

Published on: April 26, 2024

1.3K
Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

1.1K

Related Experiment Videos

Last Updated: Feb 15, 2026

Author Spotlight: An Economic and Efficient Method for Quantitative Evaluation of Bone Microarchitecture in a Murine Osteoporosis Model
06:59

Author Spotlight: An Economic and Efficient Method for Quantitative Evaluation of Bone Microarchitecture in a Murine Osteoporosis Model

Published on: September 8, 2023

3.6K
Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention
03:56

Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention

Published on: April 26, 2024

1.3K
Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

1.1K
  • Evaluation of drug mechanisms of action, such as anabolic and antiresorptive effects.

    • Main Results:

    • Ten-year denosumab treatment shows benefits, but stopping it may elevate early vertebral fracture risk in patients with existing vertebral fractures.
    • Teriparatide demonstrates superior efficacy over risedronate in preventing both vertebral and clinical fractures in high-risk individuals.
    • Romosozumab functions as an anabolic agent for osteoporosis treatment.
    • Atypical femoral fractures linked to bisphosphonate therapy may be more prevalent in patients with specific anatomical characteristics.

    Conclusions:

    • Osteoporosis treatment selection is contingent upon the specific drug and the patient's individual fracture risk profile.
    • Understanding the long-term effects and discontinuation risks of treatments like denosumab is crucial.
    • Comparative effectiveness of agents like teriparatide and risedronate supports individualized treatment strategies for high-risk osteoporosis patients.